INTRODUCTION AND OBJECTIVES: Enzalutamide and abiraterone are frequently used for castration-resistant prostate cancer (CRPC), because of improved tolerability of them compared to taxanes. However, there are no predictive biomarkers to make a decision of how to best use abiraterone or enzalutamide. The aim of this study was to clarify the impact of serum testosterone in a decision-making of treatment selections (enzalutamide or abiraterone) for CRPC.
METHODS: We retrospectively evaluated consecutive CRPC patients treated at our institution and other satellite hospitals between 2013 and May 2016. A total of 115 patients received enzalutamide or abiraterone for CRPC and had serum testosterone measure at the initiation of the treatment were included in this study. The patients were divided into two groups by serum testosterone before enzalutamide or abiraterone: 54 in the testosterone <5 ng/dl group and 61 in the testosterone 5 ng/dl group. Prostate-specific antigen (PSA) response rates (defined as 50% PSA declines), PSA progression-free survival (PSA-PFS), and overall survival (OS) were compared between groups.
RESULTS: A total of 72 patients were treated with enzalutamide and 43 with abiraterone. In the testosterone <5 ng/dl group, the PSA response rates were significantly lower with enzalutamide than that with abiraterone (32% vs. 62%, p¼0.033), whereas there was no difference in the testosterone 5 ng/dl group (81% vs. 93%, p¼0.429). During the median follow-up period of 12 months, 68 men (59%) had PSA relapse. In the testosterone <5 ng/dl group, the median PSA-PFS was significantly lower with enzalutamide than that with abiraterone (2.8 months vs. 6.4 months, p¼0.004) (Figure) . Likewise, it was significantly lower with enzalutamide than that with abiraterone in the testosterone 5 ng/dl group (7.6 months vs. no available, p¼0.004) (Figure) . Multivariate analysis reveals that testosterone 5 ng/dl was an independent predictive factor for PSA-PFS (HR 3.1, p<0.001). However, there was no significant difference in the median OS according to the different testosterone groups.
CONCLUSIONS: This result suggests that serum testosterone level is a useful biomarker in a decision-making of treatment selections in the novel hormonal therapy for CRPC.
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Taehyoung Lee*, Hamilton, Canada; Stuti Tanya, London, Canada; Bobby Shayegan, Hamilton, Canada INTRODUCTION AND OBJECTIVES: We investigated whether lower testosterone threshold compared to traditionally accepted level of castrate-level testosterone (< 50 ng/dl) has an impact on time to progression to castrate-resistant prostate cancer (CRPC) in patients undergoing continuous androgen deprivation therapy (ADT).
METHODS: A single-center, prospective review of 153 consecutive patients undergoing ADT from 2006 to 2016 was performed. Patients were excluded from the analysis if they received intermittent ADT, concurrent ADT with external beam radiation therapy, or if they did not achieve castrate-level testosterone (< 50 ng/dl). Serum testosterone was measured every three months after initiation of ADT. Patients were categorized based on their 1-year mean testosterone value (< 20 ng/dl, 20-32 ng/dl, 32-50 ng/dl, > 50 ng/dl) and outcome measures were compared. Progression to CRPC was assessed with the Kaplan-Meier method. Statistical analysis was performed using the log-rank, Breslow, and Tarone-Ware tests to compare the groups.
RESULTS: A total of 112 patients were included in the analysis. Median age at diagnosis was 67.9 (range: 50.9-89.1). Median follow-up Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e713
